poisar

Stocks · News reference

Zevra Therapeutics Reports Third Quarter 2026 Financial Results

Fiscal.ai

Zevra Therapeutics announced its financial results for the third quarter ended September 30, 2026, reporting $37.8 million in net revenue.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
fiscal.ai
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. SEC EDGARSEC EDGAR

    8-K filing — ZEVRA THERAPEUTICS, INC. (ZVRA)

    Filed: 2026-11-03 AccNo: 0001434647-26-000085 Size: 321 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits